In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtech Stakeholders Must Speak The Common Language Of Innovation And Reward Value

Executive Summary

The current system of paying for medical technology includes perverse incentives, which means that the full benefits that innovation can deliver are not being accessed. So says AdvaMed chairman Nadim Yared, who believes the US association's new "value framework" is the way forward for medtech stakeholders. A key element is ensuring that all players speak a common language – one that also recognizes and promotes appropriate ways of paying for innovation.

You may also be interested in...



Pivotal US Medtech Value Initiative Gaining Traction

As the US health care system shifts from a fee-for-service to a value-based approach, In Vivo asks Don May, EVP for Payment and Healthcare Delivery Policy at AdvaMed, about the association's renewed push behind the value frameworks and what he hopes the industry's drive to build on patient engagement, among other aims, will achieve.

AdvaMed: Medtech Needs Voice in Value-Based Health-Care Models

New frameworks issued by the trade group attempt to press the industry's view of "value" and how it should be measured for medical devices.

CVRx’s Investment In HF And Wider Medtech Industry Set To Pay Off

CVRx president and CEO Nadim Yared believes his company’s second-generation chronic heart failure device could present a serious commercial challenge to the traditional major players in the field. Meantime, with 10 years under his belt as CEO, Yared is focused on building the company, rather than on exits.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1122113

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel